G1 Therapeutics Inc (GTHX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

700 PARK OFFICES DRIVE RESEARCH TRIANGLE PARK, NC 27709

G1 Therapeutics, Inc. is a pharmaceutical company. The Company develops novel therapeutics for the treatment of oncology and breast cancer. G1 Therapeutics serves the healthcare sector in the United States.

Data as of 2020-11-22
Market Cap479.759 Million Shares Outstanding38.046 Million Avg 30-day Volume961.742 Thousand
P/E Ratio-4.3 Dividend Yield EPS-2.91
Price/Sales16.694 Price cash flow ratio Price free cash flow ratio-5.8
Book Value5.19 Price to Tangible Book2.43 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.148004
BETA2.04939 52-week High/Low31.38 / 8.8 Stddev0.257499
View SEC Filings from GTHX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 2 -50.0% 0 (0.0%) 1 (0.06%) -100.0%
Funds Holding: 120 102 17.65% 35 (2.3%) 28 (1.82%) 25.0%
13F shares: 29.629 Million 28.808 Million 2.85% 8.096 Million 7.932 Million 2.07%
% Ownership 77.9401 75.7814 2.85% 21.2981 20.8667 2.07%
New Positions: 26 16 62.5% 12 6 100.0%
Increased Positions 39 38 2.63% 11 11 0.0%
Closed Positions 7 16 -56.25% 4 10 -60.0%
Reduced Positions 29 26 11.54% 7 5 40.0%
Total Calls 2.402 Thousand 10.405 Thousand -76.91%
Total Puts 154.5 Thousand 11.2 Thousand 1279.46% 96.9 Thousand
PUT/CALL Ratio 64.32 1.08 5855.56% 5855.56%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GTHX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GTHX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

50 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MUIR GLENN P

170,969 2020-11-18 2

HANSON JAMES S. GENERAL COUNSEL

  • Officer
4,000 2020-09-04 2

RUDNICK SETH

  • Director
0 2020-06-11 1

ESHELMAN FREDRIC N

  • Director
0 2020-06-11 1

DEESE WILLIE A

  • Director
0 2020-06-11 1

SCHWALM CYNTHIA

  • Director
0 2020-06-11 1

NICHOLSON GARRY A

  • Director
0 2020-06-11 1

BAILEY JOHN E. (JACK) JR.

  • Director
0 2020-06-11 3

GUPTA SOMA CHIEF COMMERCIAL OFFICER

0 2020-03-31 2

VELLECA MARK A. PRESIDENT AND CEO

37,000 2020-03-13 3

MALIK RAJESH CH. MEDICAL OFFICER & SVP R&D

29,200 2020-03-13 3

MOSES JENNIFER K. CFO

11,000 2020-03-13 3

MURDOCK TERRY L CHIEF OPERATING OFFICER

0 2020-02-06 1

DEMAREE JOHN CHIEF COMMERCIAL OFFICER

0 2020-02-06 1

AVAGLIANO MARK CHIEF BUSINESS OFFICER

0 2020-02-06 1

WITTY ANDREW

  • Director
0 2019-06-12 0

STRUM JAY CHIEF SCIENTIFIC OFFICER

129,237 2019-01-02 0

PHILLIPS BARCLAY A SVP & CHIEF FINANCIAL OFFICER

0 2019-01-02 0

THORP CLAY

HATTERAS VENTURE ADVISORS IV SBIC, LLC

HATTERAS VENTURE PARTNERS IV SBIC, LP

INGRAM ROBERT ALEXANDER

CRUMPLER JOHN

LEE KENNETH B JR

REED DOUGLAS MD

  • 10% Owner
3,237,711 2018-05-30 0

MEDIMMUNE VENTURES, INC.

  • 10% Owner
2,950,630 2017-12-15 0

SHAFFER CHRISTY L

  • Director
995 2017-11-30 0

RA CAPITAL MANAGEMENT, LLC

RA CAPITAL HEALTHCARE FUND LP

KOLCHINSKY PETER

  • FMR 10% OWNER SEE FOOTNOTE (2)FMR 10% OWNER SEE FOOTNOTE (2)FMR 10% OWNER SEE FOOTNOTE (2)
No longer subject to file 2017-05-22 0

ESHELMAN VENTURES, LLC

  • 10% Owner
3,439,151 2017-05-22 0

MOSSINGHOFF GREGORY J CHIEF BUSINESS OFFICER

  • Officer
0 2017-05-16 0

RIVERS TYRELL

  • Director
0 2017-05-16 0

THORP CLAY

  • 10% Owner
213,114 2017-05-16 0

ESHELMAN FREDRIC N

ESHELMAN VENTURES, LLC

  • Director
  • 10% Owner
0 2017-05-16 0

SULLIVAN TIMOTHY EUGENE

  • Director
0 2017-05-16 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MUIR GLENN P

2020-11-19 16:54:08 -0500 2020-11-18 P 50,000 $13.50 a 170,969 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments